Zura Bio Limited (NASDAQ:ZURA) Director Sells $2,734,458.09 in Stock

Zura Bio Limited (NASDAQ:ZURA) Director Parvinder Thiara sold 1,001,633 shares of the business’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $2.73, for a total transaction of $2,734,458.09. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Zura Bio Price Performance

Zura Bio stock opened at $3.00 on Thursday. The firm has a fifty day simple moving average of $4.12 and a two-hundred day simple moving average of $4.03. Zura Bio Limited has a twelve month low of $2.00 and a twelve month high of $6.35.

Zura Bio (NASDAQ:ZURA) last released its earnings results on Thursday, November 7th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). As a group, research analysts anticipate that Zura Bio Limited will post -0.65 EPS for the current year.

Analyst Ratings Changes

ZURA has been the subject of a number of research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zura Bio in a research report on Friday, October 18th. Leerink Partnrs upgraded shares of Zura Bio to a “strong-buy” rating in a research report on Monday, November 4th. HC Wainwright reissued a “neutral” rating and issued a $5.00 price target on shares of Zura Bio in a report on Monday, November 18th. Leerink Partners initiated coverage on shares of Zura Bio in a report on Monday, November 4th. They set an “outperform” rating and a $15.00 price objective for the company. Finally, Piper Sandler reissued an “overweight” rating and issued a $26.00 target price on shares of Zura Bio in a research note on Thursday, September 19th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Zura Bio has an average rating of “Buy” and an average target price of $15.80.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Zura Bio during the 3rd quarter valued at $46,000. AQR Capital Management LLC bought a new stake in shares of Zura Bio in the second quarter worth about $43,000. SG Americas Securities LLC purchased a new position in Zura Bio during the 3rd quarter valued at about $62,000. Renaissance Technologies LLC raised its position in Zura Bio by 51.3% during the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock valued at $61,000 after purchasing an additional 5,900 shares during the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new stake in Zura Bio in the 3rd quarter worth approximately $71,000. Institutional investors own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.